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Background/aim: Pulmonary rehabilitation (PR) has proven useful in patients with chronic obstructive pulmonary disease (COPD),
but the benefits decrease over time. We evaluated the effects of a structured follow-up program after PR on patient pulmonary function,
dyspnea, body composition, exercise capacity, quality of life, psychological status, i-BODE index, hospitalization status, 5-year survival
rate. We explored whether this follow-up program could serve as a maintenance program.
Materials and methods: COPD patients who completed PR attended follow-up visits over 5 years. We administered incremental (ISWT),
endurance shuttle walk tests (ESWT), measured body (BMI), fat-free mass indices (FFMI), recorded modified Medical Research Council
(mMRC), St. George’s respiratory questionnaire (SGRQ), anxiety-depression scores. We also noted the forced expiratory volume in 1 s
(FEV1), the forced vital capacity (FVC), the forced midexpiratory flow (FEF25-75), hospitalization, survival rates before, after PR, and
in years 1, 2, 3, 5. This was a retrospective observational study.
Results: Thirty-three COPD patients with a mean age of 58 ± 8 years were enrolled. Twenty-seven (82%) were male. The mean FEV1
was 47 ± 16% of the predicted. After PR, the mMRC scale, SGRQ, anxiety, depression scores; i-BODE index; ISWT, ESWT results
improved (all p < 0.001), with the improvements persisting through the first year. Patient body composition, pulmonary function did
not differ from the baseline over the 5 years (except for a decrease in the FEF25-75 value in year 5; p = 0.003). The hospitalization rate,
i-BODE index did not change significantly over the 5 years, the improvements in the ISWT, ESWT outcomes were preserved for 3 years
(p = 0.013/0.005, respectively). The quality-of-life, anxiety scores deteriorated in year 1 (both p < 0.001) and year 3 (p = 0.005/0.010,
respectively). The dyspnea, depression scores increased progressively over the 5 years.
Conclusion: Structured follow-up programs with visits at 6-month intervals may effectively maintain improvements in COPD. Longterm randomized controlled studies are needed to verify these results.
Key words: COPD, structured pulmonary rehabilitation programs, exercise capacity, dyspnea

1. Introduction
Pulmonary rehabilitation (PR) effectively improves the
quality of life, exercise capacity, dyspnea, anxiety, and
depression of patients with chronic obstructive pulmonary
disease (COPD) [1–4]. Recently, it was reported that PR
was optimal in terms of improving dyspnea, the quality
of life, and exercise capacity in patients of all COPD
grades [5]. PR seeks to improve both the physical and
psychological conditions of patients and promote longterm adherence to health-enhancing behaviors [2]. In
several clinical trials, it was found that after 6–12-week
PR programs, the benefits were preserved for about 12–
18 months in the absence of any specific maintenance
[1–4]. However, the benefits of PR decrease over time;

maintenance strategies include community and homebased programs. A few studies found that long-term (> 12
months) maintenance programs effectively maintained
PR benefits [6–8]. A recent study also found that a PR
maintenance program preserved PR efficacy for more
than 3 years [9].
No optimal maintenance program type, content, level
of supervision, frequency, or duration has been identified.
Here, we present the effects of our structured follow-up
program (delivered after supervised multidisciplinary
PR) on the maintenance of improvements and the
hospitalization and survival rates over a 5-year period. We
explored whether a structured follow-up program could
serve as a useful maintenance program for COPD patients.
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426 COPD patients who were refered to PR program between March 2007- December 2010

Patient who did not complete the program (n=125)
Patients having missing datas (n=16)
Lost to follow up during five year (n=215)
Exacerbation during PR programs or at the time of
assessments for the follow-ups. (n=37)

Study population (n=33)
Figure 1. Flow-diagram.

2. Materials and methods
2.1. Study design
We evaluated data on COPD patients who completed PR
between March 2007 and December 2010 and attended
follow-ups over the following 5 years. This was thus
a retrospective, observational real-life study. Written
informed consent was routinely obtained prior to PR.
The Atatürk Chest Disease and Research Hospital review
board approved the study prior to commencement.
2.2. Study population
All COPD diagnoses were confirmed by the chest
physician of the PR center prior to PR; this is a criterion
of the Global Initiative for Chronic Obstructive Lung
Disease1 [10]. We excluded patients for whom data were
missing, those lost to follow-up over the 5 years, and
those evidencing exacerbations during PR or follow-up
(Figure 1). Patients were grouped by COPD stage based
on the postbronchodilator forced expiratory volume in 1
s (FEV1) as follows: stage 1, FEV1/FVC < 70% and FEV1
≥ 80% of the predicted value; stage 2, FEV1 between 50%
and 80% of the predicted value; stage 3, FEV1 between
30% and 50% of the predicted value; and stage 4, FEV1 <
30% of the predicted value1 [10].
2.3. Outcome parameters
We evaluated the exercise capacity, quality of life, perceived
dyspnea, pulmonary function, body composition, and
psychological status of the patients before and immediately

after the PR program, and in years 1, 2, 3, and 5 of followup. Exercise capacity was evaluated using the incremental
shuttle walk test (ISWT) and endurance shuttle walk
test (ESWT) [10]. Both tests adhered to field walking
test guidelines [11]. The minimal clinically important
difference (MCID) in the ISWT is 35–36 m [12].
Health-related quality of life was assessed using
the St. George’s respiratory questionnaire (SGRQ)
[13], and dyspnea was evaluated using the modified
Medical Research Council (mMRC) scale [14]. We used
spirometry (AS-507 device; Minato Medical Science,
Tokyo, Japan) to determine the FEV1, forced vital capacity
(FVC), forced midexpiratory flow (FEF25-75), and the
FEV1/FVC ratio, in line with American Thoracic SocietyEuropean Respiratory Society (ATS-ERS) guidelines
[15]. Bioelectrical impedance was applied to assess
body composition using a Tanita TBF-300A Total Body
Composition analyzer (Tokyo, Japan). The body mass index
(BMI) and fat-free mass index (FFMI) were calculated as
body mass (for the BMI) and fat-free mass (for the FFMI)
in kilograms divided by the square of the height in meters.
The Hospital Anxiety and Depression (HAD) scale scores
were used to assess psychological status [16].
2.3.1. The i-BODE index
To calculate the validated i-BODE index [17], the 6-min
walking distance (6MWD) was replaced by the ISWT
distance. It was given in Table 1.

Global Initiative for Chronic Obstructive Lung Disease (2020). Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive
Pulmonary Disease [online]. website: http://goldcopd.org [accessed 10 March 2019].
1
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Table 1. i – BODE index
Variable

0 points

1 point

2 points

3 points

FEV1 (% predicted)

≥ 65

50–64

36–49

≤ 35

ISWT distance (m)

≥ 250

150–249

80–149

˂ 80

mMRC scale score

0–1

2

3

4

BMI (kg/m )

> 21

≤ 21

2

2.4. PR program
Patients participated in a hospital-based, outpatient,
multidisciplinary, comprehensive PR program on
two half-days per week over 8 weeks. The program
featured exercise training, education, and nutritional
and psychosocial support. Educational sessions hosted
by a chest physician, two physiotherapists, a dietician, a
nurse, and a psychologist focused on normal pulmonary
anatomy and physiology, COPD pathophysiology,
communication with healthcare providers, breathing
strategies, airway clearance techniques, the roles of
medications and why they were prescribed, effective use
of respiratory devices, the benefits afforded by exercise
and physical activity, energy conservation during daily
living, a healthy diet, dietary advice, early recognition
and treatment of exacerbations, leisure activities, coping
with disease, self-management, and psychosocial issues
[2]. Each session ran for approximately 2 h on separate
days in a small-group setting at both the beginning
and end of PR. Individualized education sessions were
scheduled at each follow-up depending on patient needs.
Psychological and nutritional support sessions were oneon-one sessions. Psychosocial support sessions focused
on coping strategies, cognitive behavior therapy, and
stress management [2]. Nutritional intervention sessions
included the evaluation of body composition, nutritional
status, and nutritional interventions (for example, oral
nutritional support) depending on individual daily caloric
intake. Patients who were underweight (<21 kg/m2), who
exhibited unintentional weight loss of >5% over 6 months,
and with an FFMI < 17 kg/m2 for males or <15 kg/m2 for
females received oral nutritional support [2,3,18].
Exercise training featured 8 weeks of upper- and
lower-limb endurance and resistance training. Endurance
training included 30 min of endurance exercise (15 min on
a treadmill and 15 min on a stationary bicycle) at 85% of
each patient’s VO2 peak calculated from the ISWT. Fifteenminute warm-up and cool-down periods were allowed.
Quadriceps resistance training featured leg extensions
using free weights on 2 days/week for 8 weeks, with one
repetition allowed, commencing at 45% for two sets (10
repetitions/set) and increasing to 70% for three later
sets. Resistance training of the shoulder girdle and elbow

muscles featured one set of 10 repetitions, commencing at
500 g and progressing to 1–1.5 kg. All training followed
guideline recommendations [19,20].
2.5. Follow-up
A 5-year follow-up was routine until 2015; the follow-up
duration then decreased to 3 years because of the very
large number of patients. Follow-up was scheduled at
3-month intervals in year 1 after supervised outpatient PR
and every 6 months thereafter. Each follow-up included
a physical examination; medical treatment optimization;
the ISWT and ESWT; determination of the BMI, FFMI,
and mMRC scale and SGRQ scores; pulmonary function
testing; and interviews with a psychologist and dietician.
Exercise training was represcribed by reference to the PR
level at each follow-up. Individual needs and the need
for education were evaluated at each follow-up. When
a home program was suggested, educational materials
including pictures and the schedule of warm-up, cooldown, and breathing exercises as well as walking and
resistance training were explained in detail. Endurance
training (walking for 30 min) was scheduled based on a
target VO2 (85% of the individual’s VO2 peak calculated
using the ISWT). Patients were told to walk more as
dyspnea decreased (to Borg ratings of 4–6). When Borg
ratings of 4–6 were attained, higher-intensity walking was
prescribed (to 85% of the individual’s peak VO2 from the
ISWT). The resistance training level (using sandbags or
bottles filled with water, sand, or beans) depended on the
muscle strength evident on follow-up. Patients were told
that they could perform one or two extra repetitions over
two consecutive days. Patients were encouraged to exercise
at least 2–3 days per week. Oral nutritional therapy
continued if needed. All PR reassessments were recorded.
2.6. Statistical analysis
All statistical analyses were performed with the aid of the
Statistical Package for the Social Sciences ver. 18.0 (SPSS,
Chicago, IL, USA). A p-value < 0.05 was regarded as
indicating significance. Data are presented as the means ±
standard deviations or as medians (interquartile ranges).
The normality of the data distributions was explored
using the Shapiro–Wilk test. Changes in variables with
a nonparametric distribution over time (SGRQ anxiety,
depression scores, ESWT values) were analyzed using the
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Friedman test, followed by multiple Wilcoxon signedrank tests. This yielded p-values which were affected by
the number of groups. Changes in normally distributed
variables over time (the number of hospitalization,
mMRC score, BMI, FFMI, FEV1,FVC, FEF 25-75, ISWT
values, i-BODE index) were assessed using a general linear
model for repeated measures featuring the Bonferroni
adjustment.
3. Results
We retrospectively enrolled 33 COPD patients with a mean
age of 58 ± 8 years, of whom 27 (82%) were male. The mean
FEV1 was 47 ± 16% of the predicted value, the mean FVC
was 62 ± 17% of the predicted value, and the mean FEV1/
FVC ratio was 60 ± 10. Based on spirometry, no patient
had stage 1 disease, 14 (42%) had stage 2 disease, 12 (36%)
had stage 3 disease, and 7 (21%) had stage 4 disease. Three
(9%) patients were current smokers, and 24 (73%) were
former smokers [median 30 (60) pack-years]. The mean
number of hospitalizations in the year prior to PR was
0.36 ± 0.60. The mean mMRC scale score was 2.5 ± 0.7,
the mean SGRQ total score was 52 (30), the mean ISWT
distance was 291 ± 100 m, and the median ESWT result
was 8 (15) min. After a supervised 8-week PR program,
the ISWT (Figure 2) and ESWT (Figure 3) results; mMRC
scale, SGRQ, anxiety, and depression scores; and i-BODE
index immediately improved (all p < 0.01); however, the
FEV1, FVC, BMI, and FFMI did not improve (Table 2).

We found no differences in the BMI and FFMI after
PR or between follow-up visits (p = 0.476, p = 0.141,
respectively) over the 5-year period. The mMRC scale
scores increased significantly in each of the first 3 years
compared to the score at the preceding follow-up (p <
0.001, p = 0.025, p = 0.025, respectively) and exceeded
the pre-PR value in year 2. The SGRQ scores increased
in years 1 and 3 (p < 0.001, p = 0.005) but only exceeded
the pre-PR value in year 5. The ISWT and ESWT results
decreased significantly in only year 3 (p = 0.013, p = 0.005,
respectively). The ISWT and ESWT results exceeded the
pre-PR values in year 5 (Figures 2 and 3). Anxiety increased
significantly in year 1 (p < 0.001) and year 3 (p = 0.010),
and the anxiety score exceeded the pre-PR score in year
3. The depression score increased in year 1 (p < 0.001),
exceeding the pre-PR value, but then did not change
significantly (Table 2). The number of hospitalizations
decreased significantly in year 1 (p = 0.006) and did not
change significantly thereafter (p = 0.32, 0.9, and 0.20
for years 2, 3, and 5, respectively) (Figure 4). The FEV1
and FVC did not change over the 5-year period (FEV1:
p = 0.123, 0.512, 0.104, 0.923, and 0.823; FVC: p = 0.066,
0.072, 0.524, 0.312, and 0.120, respectively). The FEF 25-75
values decreased significantly in year 5 (p = 0.003) (Table
2). The i-BODE index increased significantly from 3.9 ±
2.0 to 2.8 ± 1.6 (p < 0.001) and then to 3.5 ± 1.3 (p = 0.010)
in year 1 and did not change significantly thereafter. No
patient died during the 5-year period.

5th year

3rd year

2nd year

1st year

Before PR

0.0

0.1

0.2
Mean values

0.3

PR: pulmonary rehabilitation

Figure 2. Incremental shuttle walking test (ISWT) values during 5-year period.
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5th year

3rd year

2nd year

1st year

After PR

Before PR

0

50

100

150

200
250
Mean values

300

350

400

PR: pulmonary rehabilitation

Figure 3. Endurance shuttle walking test (ESWT) values during 5-year period.

4. Discussion
We found that the dyspnea, exercise capacity, quality of life,
anxiety, and depressive symptoms improved in the COPD
patients and the number of hospitalizations and i-BODE
index decreased after multidisciplinary, comprehensive,
supervised hospital-based outpatient PR and that the
improvements were maintained over 1 year. Our structured
follow-up program (visits at 6-month intervals) may serve
as a maintenance program because the decreasing trends
in the i-BODE index and the number of hospitalizations
persisted for 5 years, and the improvement in exercise
capacity persisted for up to 3 years. However, the quality
of life and anxiety level deteriorated in both years 1 and 3.
The follow-up program did not maintain the PR-induced
improvements in dyspnea or depressive symptoms, but
it did preserve baseline pulmonary functions and body
composition.
Many COPD patients exhibit dyspnea, causing
exercise intolerance, which reduces the quality of life, and
compromises psychological status. COPD management
seeks to reduce symptoms, disease severity, and the number
of exacerbations and to improve exercise capacity and
health status. This lessens the social and economic burden
of disease. PR improves dyspnea, exercise capacity, the
quality of life, and psychosocial status; reduces healthcare
requirements; and improves the survival of COPD patients
whose lung function does not change [1–4, 21–24], We
found that, immediately after PR, dyspnea, exercise
capacity, the quality of life, anxiety, depressive symptoms,

the number of hospitalizations, and the i-BODE index
improved without any change in pulmonary function,
which generally declines over time. The FEV1 decline is
usually greater in patients with moderate COPD than in
those with severe-to-very severe COPD [25, 26]. An annual
15% FEV1 change is clinically meaningful [27]. Regular
physical activity slows the decrease in lung function and
lessens the risk of COPD development in current smokers
[28]. In another study, a 2-year maintenance program
following PR prevented an acceleration in FEV1 decline
in patients with COPD. In our study, the FEV1 did not
decrease significantly (the changes were <15%). This
may be attributable to regular exercise, education, the
checking of adherence to medications at every follow-up,
quit-smoking sessions, and the small number of current
smokers. It is thought that the decrease in FEF25-75 over
time may reflect a reduction in exercise capacity. A recent
study found a strong correlation between the FEF25-75
and exercise capacity [29].
It is important to preserve the benefits of PR long-term.
Several strategies have been tested, including telephone
contact, monthly supervised sessions, home exercise
training [with or without a weekly (supervised) outpatient
session], repeat PR, and network programs [9, 29–33]. Our
6-month follow-up program featured multidisciplinary
assessments, interviews with a psychologist and dietician,
education, and repeated prescription of home exercise
training. Although no optimal maintenance program
has yet been defined, any such program must consider
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Table 2. The values of parameters.
p

1st
year

p

2nd year

p

3rd year

Number of hospitalization 0.36 ± 0.60 -

-

0.06 ± 0.24

0.006

0.15 ± 0.45

0.32

0.15 ± 0.50 0.989

0.33 ± 0.90 0.200

BMI (kg/m )

27 ± 6

27 ± 6

0.476

27 ± 6

0.564

27 ± 6

0.665

28 ± 6

0.072

27 ± 5

0.089

FFMI (kg/m2)

20 ± 3

20 ± 3

0.141

20 ± 3

0.153

20 ± 3

0.232

20 ± 3

0.432

20 ± 3

0.221

FEV1 % of predicted

47 ± 17

47 ± 17

0.123

46 ± 17

0.512

44 ± 16

0.104

44 ± 16

0.923

44 ± 17

0.823

FVC % of predicted

61 ± 17

61 ± 18

0.066

60 ± 17

0.072

59 ± 18

0.524

59 ± 17

0.312

59 ± 15

0.120

FEF 25-75% of predicted

25 ± 5

25 ± 5

0.426

24 ± 7

0.072

23 ± 7

0.256

23 ± 7

0.672

20+6

0.003

SGRQ score

52 (30)

29 (13)

<0.001

43 (18)

<0.001

40 (19)

0.492

55 (25)

0.005

58 (27)

0.304

mMRC score

2.5 ± 0.7

1.9 ± 0.6

<0.001

2.4 ± 0.5

<0.001

2.7 ± 0.6

0.025

3.1 ± 0.6

0.025

3.3 ± 0.7

0.800

ISWT (meter)

291 ± 100

375 ± 100 <0.001

353 ± 100

0.061

364 ± 120

0.258

334 ± 123

0.013

343 ± 127

0.257

ESWT (min)

8 (15)

20 (10)

<0.001

20 (15)

0.102

20 (15)

0.879

7 (16)

0.005

6 (16)

0.394

Anxiety score

8 (3)

5 (4)

<0.001

8 (2)

<0.001

8 (4)

0.566

10 (2)

0.010

10 (2)

0.564

Depression score

9 (4)

5 (3)

<0.001

9 (3)

<0.001

10 (3)

0.136

10 (2)

0.149

10 (2)

0.1680

i-BODE index

3.9 ± 2.0

2.8 ± 1.6

<0.001

3.5 ± 1.3

0.010

3.8 ± 1.3

0.102

4.3 ± 1.6

0.123

4.5 ± 1.6

0.402

Before PR

p

5th year

p

BMI: body mass index, FFMI: fat-free mass index, FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, FEF25-75: forced midexpiratory flow, SGRQ:
St. George’s respiratory questionnaire, mMRC: modified Medical Research Council, ISWT: incremental shuttle walking test, ESWT: endurance shuttle walking
test, i-BODE index: body-mass index, airflow obstruction, dyspnea, and exercise. Data were given as mean ± standard deviation and median (interquartile range)
according to the normality of data distribution.
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5th year

3rd year

2nd year

1st year

After PR

Before PR

0

2

4

6

8
10
12
The Median values

14

16

18

20

PR: pulmonary rehabilitation

Figure 4. The number of hospitalizations during 5-year period.

the structure and resources of PR units/centers. It is not
surprising that different models yield different results.
One review found that supervised exercise programs after
primary PR appeared to be more effective than usual care
in terms of preserving exercise capacity for 6 months but
not over 1 year. Also, the quality of life did not improve
[6]. A cohort study of COPD patients who completed 10
weeks of comprehensive structured home-based PR found
that the patients who continued the prescribed exercise at
the end of PR maintained their improvements in exercise
capacity and psychological and cognitive functioning to
the 1-year follow-up [34]. In our study, the gains in exercise
capacity, dyspnea, quality of life, and psychological status
were preserved in year 1. In a recent study featuring a
maintenance network program, improvements in exercise
capacity and the quality of life due to PR were preserved for
4 years and the dyspnea benefits for 5 years [9]. In a 3-year
follow-up study, after a home exercise program following
supervised 8-week PR, the beneficial effects as revealed by
the i-BODE index and the 6MWD were maintained for 2
years, but the quality-of-life benefits were not (including
the score for the dyspnea domain of the chronic respiratory
questionnaire [8]. In our follow-up program with 6-month
visits, the improvement in exercise capacity was preserved
for up to 3 years. The quality of life deteriorated in years 1
and 3 but was better than baseline up to year 3. The i-BODE
index did not change significantly after year 1. This was not
unexpected because the three related indices (BMI, FEV1,
and exercise capacity) did not change significantly.

The most important long-term goal of PR is
survival. Several factors contribute to COPD mortality.
Hospitalization caused by COPD exacerbation is one of the
most important. Hospital admissions have been found to
decrease after PR [35]. The most obvious long-term benefit
of our program was reduced hospitalization numbers over
the 5 years. Although the baseline hospitalization number
was low, 5 years is quite long. Another study found that poor
exercise capacity increased mortality; an improvement of at
least 30 m in the 6MWD was associated with better outcomes
and lower 5-year mortality after PR [36]. In our study, PRinduced improvement in exercise capacity was preserved for
up to 3 years; the ISWT distance was 100 m greater than
the baseline value immediately after PR and 80 m more
in year 5. Both values exceeded the MCID. The repeated
prescription of home exercise training at 6-month intervals
might have contributed to the high 5-year survival rate. The
body composition also predicts mortality; we found that the
BMI and FFMI were preserved over the 5 years. The slight
decreases in pulmonary function and exercise capacity,
together with the preservation of body composition, suggest
that a structured, multidisciplinary, supervised, 8-week
follow-up PR program decelerates disease progression over
5 years. This is also supported by the preserved i-BODE
scores, decreased number of hospitalizations, and high
survival rate. Although our results are promising, long-term
randomized controlled studies are required.
However, our follow-up program did not preserve
the PR-induced improvements in dyspnea and depressive
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symptoms. Nevertheless, preservation of a better quality
of life than that at baseline for up to 3 years is important
for COPD patients, more than half of whom had stages
3–4 disease. Also, the increased dyspnea and depression
scores may reflect psychological effects rather than the
physiological mechanism of dyspnea. Taken together,
our results suggest that a structured follow-up program
featuring prescribed exercise, as well as comprehensive
program reassessment and represcription at each followup according to patient needs, contributed significantly
to the effective maintenance of PR-induced COPD
improvements.
Only a few studies on the long-term maintenance of PRinduced benefits or follow-up PR programs have appeared,
especially from countries with few PR centers/units (such
as Turkey). As this was a real-life study, our follow-up
program is applicable in practice in other PR units. The
limitations of our work are that it was a single-center study
with a limited number of patients and no control group.

Adherence to the home exercise program was not observed.
The exclusion of patients lost to follow-up over the 5 years
and those who experienced exacerbations during PR or
at the times of follow-up would have caused bias, as such
patients would likely exhibit higher hospitalization rates
and poorer outcomes.
5. Conclusion
Comprehensive,
hospital-based,
supervised,
multidisciplinary outpatient PR increased the exercise
capacity, quality of life, and psychological status of COPD
patients and decreased dyspnea for 1 year. No optimal
maintenance program after supervised PR has yet been
devised. Randomized controlled studies are needed.
However, structured follow-up at 6-month intervals
may be effective. Each visit featured comprehensive
reassessment and determination of patient needs. This
may improve exercise capacity and decrease the number
of hospitalizations.
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